Zealand Pharma A/S/ADR
No enriched coverage for $ZLDPF in the last 7 days.
No SEC Form 4 filings for $ZLDPF in the last 30 days.
See all $ZLDPF insider activity →Royalty Pharma (RPRX) agreed to a $100M deal with Zealand Pharma for rights to a rare blood disorder therapy. RPRX shares are down 1.86% to $60.58, but up 11.16% over 90 days and 70.08% over a year. Analysts debate its valuation, with some calling it 2% overvalued at $59.25, while a DCF model suggests it's heavily discounted at $195.31.
Jefferies downgraded Zealand Pharma (ZELA) from Buy to Hold and cut its price target to DKK 320 from DKK 505, citing no near-term value catalysts in 2H 2026. It reduced the probability of success for survodutide to 40% from 60% due to tolerability concerns after Phase III data. Shares fell about 2% with no Zealand-specific news.
Jefferies downgraded Zealand Pharma A/S to Hold from Buy and cut its price target to DKK320 from DKK505, citing fewer near-term catalysts. The firm lowered survodutide Phase III success odds to 40% from 60% after disappointing data. Zealand shares fell 2.7% to DKK273.40 in Copenhagen.
Recent ZLDPF coverage spans financial news, corporate actions and market movers.
Royalty Pharma (RPRX) agreed to a $100M deal with Zealand Pharma for rights to a rare blood disorder therapy. RPRX shares are down 1.86% to $60.58, but up 11.16% over 90 days and 70.08% over a year. Analysts debate its valuation, with some calling it 2% overvalued at $59.25, while a DCF model suggests it's heavily discounted at $195.31.
Jefferies downgraded Zealand Pharma (ZELA) from Buy to Hold and cut its price target to DKK 320 from DKK 505, citing no near-term value catalysts in 2H 2026. It reduced the probability of success for survodutide to 40% from 60% due to tolerability concerns after Phase III data. Shares fell about 2% with no Zealand-specific news.
Jefferies downgraded Zealand Pharma A/S to Hold from Buy and cut its price target to DKK320 from DKK505, citing fewer near-term catalysts. The firm lowered survodutide Phase III success odds to 40% from 60% after disappointing data. Zealand shares fell 2.7% to DKK273.40 in Copenhagen.
Zealand Pharma (Nasdaq: ZEAL) reported share buy-back transactions for week 27 (Jun 29–Jul 3, 2026) under its DKK 1.3bn program. It bought 170,000 shares at an average DKK 49,859,500 accumulated value; total under the program is 1,619,000 shares for DKK 487,747,300. The company holds 2,489,482 treasury shares (~3.47%).
Zealand Pharma's submission for glepaglutide approval may positively impact its stock if approved, signaling potential revenue growth.
alphai scores every news story that mentions ZLDPF with an AI model for sentiment and relevance, and aggregates insider trades from Zealand Pharma A/S/ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.
Royalty Pharma (RPRX) agreed to a $100M deal with Zealand Pharma for rights to a rare blood disorder therapy. RPRX shares are down 1.86% to $60.58, but up 11.16% over 90 days and 70.08% over a year. Analysts debate its valuation, with some calling it 2% overvalued at $59.25, while a DCF model suggests it's heavily discounted at $195.31.
2 min readJefferies downgraded Zealand Pharma (ZELA) from Buy to Hold and cut its price target to DKK 320 from DKK 505, citing no near-term value catalysts in 2H 2026. It reduced the probability of success for survodutide to 40% from 60% due to tolerability concerns after Phase III data. Shares fell about 2% with no Zealand-specific news.
2 min readJefferies downgraded Zealand Pharma A/S to Hold from Buy and cut its price target to DKK320 from DKK505, citing fewer near-term catalysts. The firm lowered survodutide Phase III success odds to 40% from 60% after disappointing data. Zealand shares fell 2.7% to DKK273.40 in Copenhagen.
4 min readZealand Pharma (Nasdaq: ZEAL) reported share buy-back transactions for week 27 (Jun 29–Jul 3, 2026) under its DKK 1.3bn program. It bought 170,000 shares at an average DKK 49,859,500 accumulated value; total under the program is 1,619,000 shares for DKK 487,747,300. The company holds 2,489,482 treasury shares (~3.47%).
2 min readPress release - No. ...
4 min readCompany announcement - No. ...
4 min readPress Release - No. ...
2 min readPress release - No. ...
2 min readCompany announcement - No. ...
2 min read
